Cover Image
市場調查報告書

PharmaPoint:類風濕性關節炎 - 歐盟5國的醫藥品的預測與市場分析

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325983
出版日期 內容資訊 英文 291 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:類風濕性關節炎 - 歐盟5國的醫藥品的預測與市場分析 PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 291 Pages
簡介

本報告提供歐盟5國 (法國,德國,義大利,西班牙,英國) 的類風濕性關節炎市場相關調查,提供您市場概要,競爭情形,主要藥物的詳細資訊和SWOT分析,並彙整主要藥物的銷售額預測,主要活動的影響分析,市場影響因素分析等資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 疾病和治療概要
    • 診斷
    • 治療指南
    • 類風濕性關節炎治療的主要處方藥
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 產品簡介 - 領導品牌
    • Enbrel (依那西普(Etanercept))
    • Humira (Adalimumab)
    • Remicade (Infliximab)
    • Simponi (golimumab)
    • Cimzia (certolizumab pegol)
    • Orencia (abatacept)
    • Actemra/RoActemra (tocilizumab)
    • Rituxan/MabThera (Rituximab)
    • Inflectra/Remsima (Infliximab的生技仿製藥)
    • Methotrexate
  • 生技仿製藥
    • 簡介
    • 在主要自體免疫疾病方面,Hospira的Inflectra和J & J的Remicade的比較
    • 免疫學機構團體的生技仿製藥
    • 開發中的生技仿製藥的數量
    • 製藥產業整體所感受到的生技仿製藥影響度
    • 類風濕性關節炎用生技仿製藥的普及率預計將依市場而有所不同
  • 其他的治療藥物

第6章 未滿足需求和機會

  • 概要
  • 開發高成本效率的治療藥
    • 未滿足需求
    • 差距分析
    • 機會
  • 預測治療反應度用的生物標記
    • 未滿足需求
    • 差距分析
    • 機會
  • 類風濕性關節炎的早期診斷
    • 未滿足需求
    • 差距分析
    • 機會
  • 個體化治療的方法
    • 未滿足需求
    • 差距分析
    • 機會

第7章 開發平台評估

  • 概要
  • 臨床開發上的潛力治療藥物
    • Sarilumab
    • Sirukumab
    • Clazakizumab
    • Cosentyx (secukinumab)
    • Tregalizumab
    • Mavrilimumab
    • Baricitinib
    • Peficitinib
    • Decernotinib
    • Filgotinib
    • Masitinib
    • RAVAX
  • 開發中的其他的醫藥品

第8章 市場預測

  • 成長因素與阻礙 - 全球課題
  • 法國
    • 預測
    • 主要的事件
    • 成長因素與阻礙
  • 德國
    • 預測
    • 主要的事件
    • 成長因素與阻礙
  • 義大利
    • 預測
    • 主要的事件
    • 成長因素與阻礙
  • 西班牙
    • 預測
    • 主要的事件
    • 成長因素與阻礙
  • 英國
    • 預測
    • 主要的事件
    • 成長因素與阻礙

第9章 附錄

目錄
Product Code: GDHC265CFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

The key drivers of this growth include an increase in the RA patient population, higher drug prices in Germany as compared with the other four major EU countries, and ample opportunities within the biosimilars market. However, the Italian government is implementing austerity measures to keep healthcare costs low, and is expected to promote the use of less expensive treatment alternatives. However, the growth of the RA market in Spain will be hindered by the implementation of austerity measures, which aim to cut healthcare costs and will thus limit the prescribing of biologic agents. The key drivers of this growth include the increasing RA patient population and the universal healthcare system, which allows all RA patients access to healthcare, while austerity measures aimed at cutting healthcare costs will serve as a barrier to market growth.

Scope

  • Overview of Rheumatoid arthritis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the 5EU from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Rheumatoid arthritis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid arthritis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Enbrel (etanercept)
    • 5.2.2. Humira (adalimumab)
    • 5.2.3. Remicade (infliximab)
    • 5.2.4. Simponi (golimumab)
    • 5.2.5. Cimzia (certolizumab pegol)
    • 5.2.6. Orencia (abatacept)
    • 5.2.7. Actemra/RoActemra (tocilizumab)
    • 5.2.8. Rituxan/MabThera (rituximab)
    • 5.2.9. Inflectra/Remsima (infliximab biosimilar)
    • 5.2.10. Methotrexate (Numerous Brands)
  • 5.3. Biosimilars
    • 5.3.1. Introduction
    • 5.3.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.3.3. Biosimilars in the Immunology Community
    • 5.3.4. By the Numbers: Biosimilars in Development
    • 5.3.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 5.3.6. Uptake of Biosimilars for RA is Expected to Vary by Market
  • 5.4. Other Therapies

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Development of Cost-Effective Therapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Biomarkers to Predict Responsiveness to Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Early Diagnosis of RA
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Sarilumab
    • 7.2.2. Sirukumab
    • 7.2.3. Clazakizumab
    • 7.2.4. Cosentyx (secukinumab)
    • 7.2.5. Tregalizumab
    • 7.2.6. Mavrilimumab
    • 7.2.7. Baricitinib
    • 7.2.8. Peficitinib
    • 7.2.9. Decernotinib
    • 7.2.10. Filgotinib
    • 7.2.11. Masitinib
    • 7.2.12. RAVAX
  • 7.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Drivers and Barriers - Global Issues
    • 8.1.1. Driver: Launch of novel drugs, including oral JAK inhibitors and novel biologics for RA
    • 8.1.2. Driver: Earlier diagnosis and treatment
    • 8.1.3. Driver: Market entry of biosimilars will bring a therapy option for those who cannot afford branded biologics
    • 8.1.4. Driver: Aging population and increasing prevalent cases of RA
    • 8.1.5. Barrier: Efforts to reduce costs in the treatment of RA
    • 8.1.6. Barrier: Lack of regulatory guidelines for biosimilars will delay their availability in some regions
    • 8.1.7. Barrier: Entry of biosimilars will create a less expensive treatment alternative
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. United Kingdom
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed RA Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic and Biosimilar Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Reviewer
    • 9.7.3. Therapy Area Director
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country across the 5EU
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) across the 5EU, 2014
  • Table 8: RA Treatment Country Profile - France
  • Table 9: RA Treatment Country Profile - Germany
  • Table 10: RA Treatment Country Profile - Italy
  • Table 11: RA Treatment Country Profile - Spain
  • Table 12: RA Treatment Country Profile - UK
  • Table 13: Leading Branded Treatments for RA 2014
  • Table 14: Product Profile - Enbrel
  • Table 15: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers
  • Table 16: 10-year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results
  • Table 17: Enbrel SWOT Analysis, 2014
  • Table 18: Product Profile - Humira
  • Table 19: Humira SWOT Analysis, 2014
  • Table 20: Product Profile - Remicade
  • Table 21: Remicade SWOT Analysis, 2014
  • Table 22: Product Profile - Simponi
  • Table 23: Simponi SWOT Analysis, 2014
  • Table 24: Product Profile - Cimzia
  • Table 25: Cimzia SWOT Analysis, 2014
  • Table 26: Product Profile - Orencia
  • Table 27: Orencia SWOT Analysis, 2014
  • Table 28: Product Profile - Actemra
  • Table 29: Actemra SWOT Analysis, 2014
  • Table 30: Product Profile - Rituxan
  • Table 31: Rituxan SWOT Analysis, 2014
  • Table 32: Product Profile - Inflectra/Remsima
  • Table 33: Inflectra/Remsima SWOT Analysis, 2014
  • Table 34: Product Profile - MTX
  • Table 35: MTX SWOT Analysis, 2014
  • Table 36: Biosimilars Pipeline for RA, 2013
  • Table 37: Physician Uptake of Biosimilar Products for RA Across the 5EU, 2014
  • Table 38: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2014
  • Table 39: Unmet Need and Opportunity in RA, 2014
  • Table 40: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 41: Product Profile - Sarilumab
  • Table 42: MOBILITY Study Part, A, Results for Sarilumab at Week 12
  • Table 43: MOBILITY Study, Part B, Results for Sarilumab at Week 52
  • Table 44: Sarilumab SWOT Analysis, 2014
  • Table 45: Product Profile - Sirukumab
  • Table 46: Sirukumab SWOT Analysis, 2014
  • Table 47: Product Profile - Clazakizumab
  • Table 48: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks
  • Table 49: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks
  • Table 50: Clazakizumab SWOT Analysis, 2014
  • Table 51: Product Profile - Cosentyx
  • Table 52: Cosentyx SWOT Analysis, 2014
  • Table 53: Product Profile - Tregalizumab
  • Table 54: Tregalizumab SWOT Analysis, 2014
  • Table 55: Product Profile - Mavrilimumab
  • Table 56: Mavrilimumab SWOT Analysis, 2014
  • Table 57: Product Profile - Baricitinib
  • Table 58: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12
  • Table 59: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52
  • Table 60: Baricitinib Phase IIb Trial, Part A: Safety at Week 12
  • Table 61: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12
  • Table 62: Baricitinib SWOT Analysis, 2014
  • Table 63: Product Profile - Peficitinib
  • Table 64: Peficitinib SWOT Analysis, 2014
  • Table 65: Product Profile - Decernotinib
  • Table 66: Phase IIb tudy of Decernotinib: ACR Responses at Week 24
  • Table 67: Decernotinib SWOT Analysis, 2014
  • Table 68: Product Profile - Filgotinib
  • Table 69: Filgotinib SWOT Analysis, 2014
  • Table 70: Product Profile - Masitinib
  • Table 71: ACR Response to Masitinib in RA (12 Weeks)
  • Table 72: ACR Responses for Masitinib in the Phase IIa ITT Population (12-82 Weeks)
  • Table 73: Masitinib SWOT Analysis, 2014
  • Table 74: Product Profile - RAVAX
  • Table 75: RAVAX SWOT Analysis, 2014
  • Table 76: Drugs in Phase II of Development for RA, 2014
  • Table 77: Global RA Market - Drivers and Barriers, 2013-2023
  • Table 78: Sales Forecasts ($m) for RA in France, 2013-2023
  • Table 79: Key Events Impacting Sales for RA in France, 2013-2023
  • Table 80: RA Market in France - Drivers and Barriers, 2013-2023
  • Table 81: Sales Forecasts ($m) for RA in Germany, 2013-2023
  • Table 82: Key Events Impacting Sales for RA in Germany, 2013-2023
  • Table 83: RA Market in Germany - Drivers and Barriers, 2013-2023
  • Table 84: Sales Forecasts ($m) for RA in Italy, 2013-2023
  • Table 85: Key Events Impacting Sales for RA in Italy, 2013-2023
  • Table 86: RA Market in Italy - Drivers and Barriers, 2013-2023
  • Table 87: Sales Forecasts ($m) for RA in Spain, 2013-2023
  • Table 88: Key Events Impacting Sales for RA in Spain, 2013-2023
  • Table 89: RA Market in Spain - Drivers and Barriers, 2013-2023
  • Table 90: Sales Forecasts ($m) for RA in the UK, 2013-2023
  • Table 91: Key Events Impacting Sales for RA in the UK, 2013-2023
  • Table 92: RA Market in the UK - Drivers and Barriers, 2013-2023
  • Table 93: Key Launch Dates of RA Products in the 5EU
  • Table 94: Key Patent Expiries
  • Table 95: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: Biosimilar Prescribing Habits in RA Across the 10MM, 2014
  • Figure 7: RA - Phase II-III Pipeline, 2014
  • Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 9: Clinical and Commercial Positioning of Sarilumab
  • Figure 10: Clinical and Commercial Positioning of Sirukumab
  • Figure 11: Clinical and Commercial Positioning of Clazakizumab
  • Figure 12: Clinical and Commercial Positioning of Cosentyx
  • Figure 13: Clinical and Commercial Positioning of Tregalizumab
  • Figure 14: Clinical and Commercial Positioning of Mavrilimumab
  • Figure 15: Clinical and Commercial Positioning of Baricitinib
  • Figure 16: Clinical and Commercial Positioning of Peficitinib
  • Figure 17: Clinical and Commercial Positioning of Decernotinib
  • Figure 18: Clinical and Commercial Positioning of Filgotinib
  • Figure 19: Clinical and Commercial Positioning of Masitinib
  • Figure 20: Clinical and Commercial Positioning of RAVAX
  • Figure 21: Sales for RA in France by Drug Class, 2013-2023
  • Figure 22: Sales for RA in Germany by Drug Class, 2013-2023
  • Figure 23: Sales for RA in Italy by Drug Class, 2013-2023
  • Figure 24: Sales for RA in Spain by Drug Class, 2013-2023
  • Figure 25: Sales for RA in the UK by Drug Class, 2013-2023
Back to Top